Home
HelpTest Code PHSP Prenatal Hepatitis Evaluation, Serum
Reporting Name
Prenatal Hepatitis EvaluationPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Useful For
Screening pregnant women for chronic hepatitis B and hepatitis C in primary care settings, with or without risk factors for hepatitis C
Determining the level of infectivity of chronic hepatitis B in pregnant women
This test is not useful for diagnosis of hepatitis B during the "window period" of acute hepatitis B virus infection (ie, after disappearance of hepatitis B surface antigen and prior to appearance of hepatitis B surface antibody).
This test should not be used as a screening test for hepatitis C in blood or human cells/tissue donors.
This test profile is not useful for detection or diagnosis of acute hepatitis C virus (HCV) in pregnancy, since HCV antibodies may not be detectable until after 2 months following exposure, and HCV RNA testing is not performed on specimens with negative HCV antibody screening test results.
Method Name
Electrochemiluminescence Immunoassay (ECLIA)
Necessary Information
Date of collection is required.
Specimen Required
Patient Preparation: For 24 hours before specimen collection, patient should not take multivitamins or dietary supplements (eg, hair, skin, and nail supplements) containing biotin (vitamin B7).
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Serum gel (red-top tubes are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 2.2 mL
Collection Instructions:
1. Centrifuge blood collection tube per manufacturer's instructions (eg, centrifuge and aliquot within 2 hours of collection for BD Vacutainer tubes).
2. Aliquot serum into a plastic vial and ship frozen (preferred).
Specimen Type
Serum SSTSpecimen Minimum Volume
1.6 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum SST | Frozen (preferred) | 84 days | |
| Refrigerated | 6 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Reference Values
HEPATITIS B VIRUS SURFACE ANTIGEN
Negative
HEPATITIS C VIRUS ANTIBODY
Negative
Interpretation
Hepatitis B virus surface antigen (HBsAg) is the first serologic marker appearing in the serum 6 to 8 weeks following hepatitis B virus (HBV) infection. A confirmed positive result for HBsAg is indicative of acute or chronic hepatitis B. In acute cases, HBsAg usually disappears 1 to 2 months after the onset of symptoms. Persistence of HBsAg for more than 6 months indicates development of either a chronic carrier state or chronic liver disease. HBs antibody (anti-HBs) appears with the resolution of HBV infection after the disappearance of HBsAg.
Hepatitis B e antigen (HBeAg) appears at approximately the same time as HBsAg and indicates that the virus is replicating and the individual is infectious. Appearance of anti-HBe after the disappearance of HBsAg and HBeAg usually indicates recovery and loss of infectivity.
Reactive hepatitis C virus (HCV) antibody screening results with cutoff index (COI) at or below 20.0 are not predictive of the true HCV antibody status; additional testing is recommended to confirm HCV antibody status.
Reactive results with COI greater than 20.0 are highly predictive (95% or greater probability) of the true HCV antibody status, but additional testing is needed to differentiate between past (resolved) and chronic hepatitis C.
A negative screening test result does not exclude the possibility of exposure to, or infection with, HCV. Negative screening test results in individuals with prior exposure to HCV may be due to low antibody levels that are below the limit of detection of this assay or lack of reactivity to the HCV antigens used in this assay. Patients with acute or recent HCV infections (<3 months from time of exposure) may have false-negative HCV antibody results due to the time needed for seroconversion (average of 8 to 9 weeks). Testing for HCV RNA using HCVRP / Hepatitis C Virus (HCV) RNA Detection and Quantification, Real-Time Reverse Transcription-PCR, Prenatal, Serum is recommended for detection of HCV infection in such patients.
Day(s) Performed
Monday through Saturday
Report Available
Same day/1 to 4 daysTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
87340
86803
G0472 (if appropriate for government payers)
87522 (if appropriate)
86707 (if appropriate)
87341 (if appropriate)
87350 (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| PHSP | Prenatal Hepatitis Evaluation | 101653-4 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| HBSAP | HBs Antigen Prenatal, S | 5196-1 |
| HCVA6 | HCV Ab Prenatal, S | 40726-2 |
Forms
If not ordering electronically, complete, print, and send 1 of the following:
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| HBAGP | HBs Antigen Prenatal, S | Yes | Yes |
| HCVSP | HCV Ab Scrn Prenatal, S | Yes | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| EAG | Hepatitis Be Ag, S | Yes | No |
| HEAB | HBe Antibody, S | Yes | No |
| HBNTP | HBs Ag Confirmation Prenatal, S | No | No |
| HCVRP | HCV RNA Detect/Quant Prenatal, S | Yes | No |
Testing Algorithm
If the hepatitis B virus surface antigen (HBsAg) result is reactive, then HBsAg confirmation testing will be performed at an additional charge. If the HBsAg confirmation result is positive, then HBe Ag and HBe antibody testing will be performed at an additional charge.
If the hepatitis C virus (HCV) antibody screen is reactive, then HCV RNA testing by reverse transcriptase-polymerase chain reaction will be performed at an additional charge.
For more information see Hepatitis B: Testing Algorithm for Screening, Diagnosis, and Management.